Maxim Group Maintains Genelux(GNLX.US) With Buy Rating, Maintains Target Price $10
Genelux Is Maintained at Buy by HC Wainwright & Co.
Genelux Analyst Ratings
Guggenheim Initiates Genelux(GNLX.US) With Buy Rating, Announces Target Price $8
Maxim Group Maintains Genelux(GNLX.US) With Buy Rating, Announces Target Price $10
Promising Growth Potential and Clinical Advancements Drive Buy Rating for Genelux Corp.
Genelux Price Target Announced at $10.00/Share by Roth MKM
Genelux Initiated at Buy by Roth MKM
Roth MKM Initiates Coverage On Genelux With Buy Rating, Announces Price Target of $10
Maxim Group Maintains Genelux(GNLX.US) With Buy Rating
Maxim Group Sticks to Their Buy Rating for Genelux Corp. (GNLX)
Genelux Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Genelux, Maintains $32 Price Target
Genelux Analyst Ratings
Genelux Analyst Ratings
Genelux Corp: Benchmark cuts target price from $30 to $25
HC Wainwright & Co. : Genelux (GNLX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $32.00.
Genelux Analyst Ratings
Buy Rating Affirmed for Genelux Corp on Strong Trial Progress and Solid Financials
Genelux Analyst Ratings